Navigation Links
Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
Date:7/9/2008

SOUTH SAN FRANCISCO, July 9 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, a chronic and potentially sight-threatening inflammation of the eye. The randomized, double-masked, placebo-controlled study will evaluate the safety and efficacy of Simulect as maintenance therapy in 56 patients. During the study, patients will undergo tapering of concomitant immunosuppressive medications, the mainstay of treatments for noninfectious uveitis. This is the second mid-stage trial for basiliximab run by Cerimon, which began a Phase IIb study for patients with moderate-to-severe, steroid-refractory ulcerative colitis (UC) in April 2007.

"The initiation of this proof-of-concept study is part of our overall strategy to seek additional indications for already marketed drugs in areas with significant unmet medical needs," stated Paul Sekhri, President and CEO of Cerimon Pharmaceuticals. "In noninfectious uveitis, we believe Simulect has the potential to significantly improve the quality of life for patients by reducing adverse events often associated with oral or topical corticosteroids while maintaining effective control of their inflammation."

Basiliximab is a monoclonal antibody that selectively blocks the interleukin-2 (IL-2) receptor. This mechanism of action provides highly targeted inhibition of the T-lymphocyte activation that is involved in serious immune-related diseases including noninfectious uveitis. In February 2006, the Company licensed basiliximab from Novartis Pharma AG for the treatment of Inflammatory Bowel Disease (IBD) and initiated a Phase IIb clinical study for the treatment of moderate-to-severe, steroid-refractory ulcerative colitis the following year. In December 2007, Cerimon entered into an agreement with Novartis to conduct a proof-of-concept study for basiliximab for the treatment of noninfectiou
'/>"/>

SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
2. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
3. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
4. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
7. Isis Pharmaceuticals Conference Call Notice
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)...  Mytrus, a technology and services company revolutionizing clinical trials, announced ... has received approval for use by Britain,s ... first time e-Consent technology will be used in a ... Mytrus was also the first electronic informed consent ... the U.S. Food and Drug Administration in 2011. It ...
(Date:8/27/2015)... CAESAREA, Israel , August 27, 2015 ... Equity today announced a private investment in public equity ... up to $28.4 million in Itamar Medical.   ... the largest shareholder of Itamar Medical and will work ... market expansion. According to the investment agreement, ...
(Date:8/27/2015)... 27, 2015 The Elekta Linac-based ... Boston on July 9th for its ... to more fully exploit the potential of advances in ... diseases. "As an established provider of sophisticated ... assume a leadership role - in collaboration with its ...
Breaking Medicine Technology:Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 4Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 5New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... increased patient loyalty at a low cost. Personalized with practice contact information and ... existing patients. Dental offices can also incorporate Calendars into seasonal mailings, thank you ...
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the Adams County ... people, all for a good cause. In its second year, the “Music With A ... Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to raise money ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Louis W. ... technology innovation to transform quality and efficiency of healthcare delivery worldwide, announced the ... and aggregated before being publicly shared to document progress and inform policy in ...
(Date:8/28/2015)... Indianapolis, IN (PRWEB) , ... August 28, 2015 ... ... employee benefits advisory organization, is pleased to welcome TJS Insurance Group as its ... to employees and clients guides them and keeps them focused on their goals. ...
(Date:8/28/2015)... ... 28, 2015 , ... The Plaintiffs Steering Committee (PSC) and ... Replacement Therapy Products Liability Litigation, are in the midst of ongoing discussion regarding ... may receive for corporate employees involved in the production or marketing of AbbVie ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4
... , , WASHINGTON , ... (National Council) is offering small emergency grants and free Mental Health ... of the devastating Haiti earthquake. , "Our thoughts are ... ones in the U.S. We commend the efforts of many agencies ...
... that launch glioblastoma multiforme, the most lethal type of brain ... scientists from The University of Texas M. D. Anderson Cancer ... the Jan. 15 issue of Clinical Cancer Research . ... also known as cancer stem cells, stifles the immune response ...
... Long-term use of low-dose versions affect women most, study finds, ... decrease bone density in young women, a new study suggests. ... years, and those on the low-dose estrogen pills appear to ... spine and whole body, according to the researchers. , "I ...
... Irritable bowel syndrome (IBS) is a common gastrointestinal ... well being. Multiple interacting mechanisms, including alterations in ... IBS aetiology. A research article to be ... World Journal of Gastroenterology addresses this question. ...
... increasing worldwide and its prognosis is very poor. ... early detection and on surgical treatment for better ... team from China retrospectively evaluated 5311 liver cancer ... December 2003. Of these, 429 (8.1%) patients were ...
... ... the new year by expanding their existing Green Bay, WI presence with the purchase ... ... technology company representing both businesses and residents has joined forces with Buildmyownsite, Inc., a ...
Cached Medicine News:Health News:Emergency Grants and Mental Health First Aid Training Available to Meet Mental Health Needs After Haiti Earthquake 2Health News:Emergency Grants and Mental Health First Aid Training Available to Meet Mental Health Needs After Haiti Earthquake 3Health News:Cancer stem cells suppress immune response against brain tumor 2Health News:Cancer stem cells suppress immune response against brain tumor 3Health News:The Pill May Decrease Bone Density 2Health News:The Pill May Decrease Bone Density 3Health News:Infinity Technology, Inc. Acquires Build My Own Site, Inc. 2
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
Medicine Products: